CEVEC Pharmaceuticals - now part of Cytiva

Register for the online seminar hosted by @CEVEC1 now part of Cytiva during the BPI Digital Week on Nov 8, 10AM EDT and learn from VP Technology Development Dr Markus Krieger how you can produce high-titer, high-quality AAV vectors as easily as antibodies. bit.ly/3Fn42ho

We are at #BIOEUROPE Oct 24–26 in Leipzig. Meet Nicole Faust, CEO, & Ulrich Kettling, CBO, via partneringONE to discuss our leading viral vector manufacturing technologies, ELEVECTA™ for stable AAV production & CAP™ Ad for RCA-free Adenoviral vectors. bit.ly/3S0QsTy

October is conference season, we're kicking it off with two exciting events: Meet @CEVEC1 at #ESGCT 29th Congress, 11-14 Oct in Edinburgh, UK #CGMesa22, 11-13 Oct in Carlsbad, CA #genetherapy #viralvector #AAV #stableAAV #elevecta bit.ly/ESGCTco | bit.ly/CGMMesa

Today @CEVEC1 becomes part of #Cytiva, a global life sciences leader. "We are excited to join Cytiva,” says Dr. Nicole Faust, #CEVEC’s CEO. “This enables new and powerful solutions for scalable (viral)vector manufacturing.“ bit.ly/3CCNEaL #genetherapy #cytiva #cevec

@CEVEC1 and @ROKOTELabs sign agreement on the use of CEVEC’s proprietary CAP® Ad Technology for the manufacturing of therapeutic and prophylactic vaccines for COVID-19 and other respiratory diseases. bit.ly/3Ul54zo #CAP #CAPAd #noRCA #RCAfree #Adeno #GeneTherapy

Meet the @CEVEC team at booth #330 at BPI Biotech Week Boston, Sep 27 – 30. Listen to the talk of Michael Muehle, Head of Viral Vector Production on Sep 28, 3:00 p.m. EDT introducing “Next Level AAV manufacturing using stable ELEVECTA® producer cells”. bit.ly/3UeZjmI

Our license partner @RZNOMICS, Inc. was granted IND approval for ph1/2a by the South Korean FDA for its lead gene therapy RZ001 targeting liver cancer. RZ001 is manufactured using @CEVEC’S CAP® Ad Technology for RCA-free Ad vectors. #CAP #CAPAd #noRCA #RCAfree #GeneTherapy

Don’t miss CEVEC’s CEO Dr. Nicole Faust discussing with industry experts topics from balancing competing interests to building trust at the @RegMedNet Panel “Developing successful advanced therapy partnerships” on July 5th, 10:00 a.m. EDT. Please register: bit.ly/3QYq2T1

Meet the CEVEC Team at 27th ESACT Meeting from June 27–29 in Lisbon and listen to the poster presentation “THE ELEVECTA HEK293 platform – An innovative, fully stable and helper virus-free AAV production system” esact.org #ELEVECTA #AAV #stableAAV #ESACT2022 #ESACT22

Read the #BioPharmInternational article and learn about @CEVEC1’s newly developed process to drastically reduce product-related host cell DNA impurities during the production of recombinant adeno-associated virus-based vectors. bit.ly/3MANsKH #AAV #GeneTherapy #ELEVECTA

Catch the opportunity to meet us at #BIO2022 in San Diego at the @CEVEC1 booth No. 4507-09 and to schedule a meeting with CEO Dr. Nicole Faust, and CBO Dr. Ulrich Kettling using the conference partnering system. bit.ly/3lVWWFu #ELEVECTA #GeneTherapy #AAV #stableAAV

CEVEC Head of Vector Production Inês do Carmo Gonçalves talked about “How to address challenges in producing #AAV vectors” at #ASGCT2022. “We truly believe #ELEVECTA to be the technology of choice to filling the gap in producing AAV vectors”. bit.ly/3N1EtTX #GeneTherapy

Meet us at #BIO2022 in San Diego from June 13 – 16 at the @CEVEC booth No. 4507-09. Schedule a meeting with Dr. Nicole Faust, CEO and Dr. Ulrich Kettling, CBO, using the conference partnering system. bit.ly/3lVWWFu #ELEVECTA #GeneTherapy #AAV #stableAAV

Only 10 days to go for the @ASGCT 25th Annual Meeting, May 16 – 19, 2022! Meet the @CEVEC team at our booth #363, listen to the presentation and attend our poster session on stable helper-virus free #ELEVECTA® producer cells for #AAV vector manufacturing. bit.ly/3sgauzj

Our online seminar will present the latest developments in using stable AAV producer cell lines and explain how the ELEVECTA® system enables fully scalable vector production without plasmid transfection or helper viruses. bit.ly/3unlFYy #ELEVECTA #AAV #stableAAV

Hooray! In person again! Meet CEVEC at the Cell & Gene Meeting on the Med in Barcelona, Spain, from April 20-22. Listen to the presentation and request a meeting with Dr. Nicole Faust, CEO and Dr. Ulrich Kettling, CBO under: bit.ly/3r8SKVM #CAPAd #ELEVECTA #GeneTherapy

Meet the @CEVEC1 team at BIO-Europe Spring from March 28-31, 2022 and learn more about our industry-leading cell lines for RCA-free adenoviral vector production and AAV manufacturing based on stable cell lines. #CAP #CAPAD #Adeno #ELEVECTA #AAV #stableAAV bit.ly/3MYbJM3

Meet the @CEVEC1 Team at the 11th @ISBioTech Spring Meeting, Norfolk, VA. Listen to the talk of Dr. Tobias Bonifert on “Helper Virus-Free AAV Production Using Fully Stable Producer Cells” on March 14, 2:20–3:00 pm EST in the Viral Vectors & Vaccines track: bit.ly/3sDzDV5

Join @CEVEC’s FREE online seminar “Manufacturing of RCA-free adenoviral vectors” on Feb 22, 2022 - 08:00 PST; 11:00 EST; 16:00 BST; 17:00 CET hosted by Dr. Nico Scheer, Senior Consultant Business Development. Register here: bit.ly/3o5oUA5 #RCAFreeAV #CAPAd #GeneTherapy

Read about @CEVEC1 proprietary #CAP® Ad platform, an outstanding technology for RCA-free #adenovirus production combining excellent safety profile, industrial scalability and productivity, in recent articles featured by @GENbio and @BioProcessIntl: bit.ly/3oQ7c4l